The role of CD40 ligand in systemic lupus erythematosus

Abstract

CD40 ligand (CD40L, also known as CD154 or gp39) is a member of the tumor necrosis superfamily of transmembrane proteins. The interaction of CD40L on activated T cells with its receptor, CD40 on B cells, is necessary for normal immune function, including B cell differentiation, germinal center formation, and antibody isotype switching. Abnormal expressionof CD40L in patients with systemic lupus erythematosus (SLE) may contribute to autoantibody production and disease pathogenesis. Although murine models of monoclonal antibodies directed against CD40L initially showed promise, human trials either have failed to demonstrate efficacy or have been associated with adverse events. This review will summarize in vitro and murine model data and human clinical trials involving anti-CD40L monoclonal antibody.

Keywords

CD 154 CD40 ligand gp 39 review systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Schwartz RH.

Models of T cell anergy: is there a common molecular mechanism?

J Exp Med 1996; 184: 1-8 .

Saeland S , Duvert V , Moreau I , Banchereau J. Human B cell precursors proliferate and express CD23 after CD40 ligation . J Exp Med 1993; 178: 113-120 .

Renshaw BR , Fanslow WC 3rd , Armitage RJ et al. Humoral immune responses in CD40 ligand-deficient mice . J Exp Med 1994; 180: 1889-1900 .

Lederman S , Yellin MJ , Cleary AM et al. T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death . J Immunol 1994; 152: 2163-2171 .

Barrett TB , Shu G , Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells . J Immunol 1991; 146: 1722-1729 .

Schubert LA , King G , Cron RQ , Lewis DB , Aruffo A , Hollenbaugh D. The human gp39 promoter. Two distinct nuclear factors of activated T cell protein-bindingelements contribute independently to transcriptional activation . J Biol Chem 1995; 270: 29624-29627 .

Cron RQ. CD154 transcriptional regulation in primary human CD4 T cells . Immunologic Research 2003; 27: 1-18 .

Allen RC , Armitage RJ , Conley ME et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome . Science 1993; 259: 990-993 .

Calingasan NY , Erdely HA , Anthony Altar C. Identification of CD40 ligand in Alzheimer’s disease and in animal models of Alzheimer’s disease and brain injury . Neurobiol Aging 2002; 23: 31-39 .

10.

Berner B , Wolf G , Hummel KM , Muller GA , Reuss-Borst MA. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis . Ann Rheum Dis 2000; 59: 190-195 .

11.

Sugiura T , Kawaguchi Y , Harigai M et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production . J Immunol 2000; 164: 6593-6600 .

12.

Heeschen C , Dimmeler S , Hamm CW et al. The CAPTURE Study Investigators . Soluble CD40 Ligand in Acute Coronary Syndromes . N Engl J Med 2003; 348: 1104-1111 .

13.

Blossom S , Chu EB , Weigle WO , Gilbert KM. CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus . J Immunol 1997; 159: 4580-4586 .

14.

Higuchi T , Aiba Y , Nomura T et al. Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease . J Immunol 2002; 168: 9-12 .

15.

Mohan C , Shi Y , Laman JD , Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis . J Immunol 1995; 154: 1470-1480 .

16.

Early GS , Zhao W , Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-likenephritis in a subset of New Zealand black ×New Zealand white mice. Response correlates with the absence of an anti-antibody response . J Immunol 1996; 157: 3159-3164 .

17.

Daikh DI , Finck BK , Linsley PS , Hollenbaugh D , Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways . J Immunol 1997; 159: 3104-3108 .

18.

Kalled SL , Cutler AH , Datta SK , Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function . J Immunol 1998; 160: 2158-2165 .

19.

Kalled SL , Cutler AH , Burkly LC. Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment . J Immunol 2001; 167: 1740-1747 .

20.

Quezada SA , Eckert M , Adeyi OA , Schned AR , Noelle RJ , Burns CM. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis . Arthritis Rheum 2003; 48: 2541-2554 .

21.

Koshy M , Berger D , Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes . J Clin Invest 1996; 98: 826-837 .

22.

Desai-Mehta A , Lu L , Ramsey-Goldman R , Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production . J Clin Invest 1996; 97: 2063-2073 .

23.

Devi BS , Van Noordin S , Krausz T , Davies KA. Peripheral blood lymphocytes in SLE -hyperexpression of CD154 on T and B lymph-ocytes and increased number of double negative T cells . J Autoimmun 1998; 11: 471-475 .

24.

Yellin MJ , D’Agati V , Parkinson G et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides . Arthritis Rheum 1997; 40: 124-134 .

25.

Vakkalanka RK , Woo C , Kirou KA , Koshy M , Berger D , Crow MK. Elevated levels and functionalcapacity of soluble CD40 ligand in systemic lupus erythematosus sera . Arthritis Rheum 1999; 42: 871-881 .

26.

Kato K , Santana-Sahagun E , Rassenti LZ et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus . J Clin Invest 1999; 104: 947-955 .

27.

Rider V , Jones S , Evans M , Bassiri H , Atsar Z , Abdou NI Estrogen increases CD40 ligand expression in T cells in women with systemic lupus erythematosus . J. Rheumatol 2001; 28: 2644-2649 .

28.

Davis JC , Totoritis MC , Rosenberg J , Sklenar TA , Wofsy D. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus . J of Rheum 2001; 28: 95-101 .

29.

Kalunian KC , Davis JC Jr , Merrill JT , Totoritis MC , Wofsy D ; IDEC-131 Lupus Study Group . Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial . Arthritis Rheum 2002; 46: 3251-3258 .

30.

Kawai T , Andrews D , Colvin RB , Sachs DH , Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand . Nat Med 2000; 6: 114-114 .

31.

Boumpas DT , Furie R , Manzi S et al. for the BG9588 study group . A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis . Arthritis Rheum 2003; 48: 719-727 .

32.

Huang W , Sinha J , Newman J et al. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus . Arthritis Rheum 2002, 46: 1554-1562 .

33.

Henn V , Slupsky JR , Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells . Nature. 1998; 391: 591-594 .

34.

Slupsky JR , Kalbas M , Willuweit A , Henn V , Kroczek RA , Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 . Thromb Haemost 1998; 80: 1008-1014 .

35.

Biancone L , Andres G , Ahn H , DeMartino C , Stamenkovic I. Inhibition of the CD40-CD40ligand pathway prevents murine membranous glomerulonephritis . Kidney Int 1995; 48: 458-684 .

36.

Boumpas DT , Furie R , Manzi S et al for the BG9588 Lupus Nephritis Trial Group . A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis . Arthritis Rheum 2003; 48: 719-727 .